Effect of Insulin Pump Use on Diabetic Ketoacidosis in Type 1 Diabetes Mellitus: A Matched Cohort Study.

diabetes mellitus diabetic ketoacidosis injection insulin pump

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
25 Feb 2021
Historique:
received: 11 01 2021
revised: 08 02 2021
accepted: 18 02 2021
entrez: 6 3 2021
pubmed: 7 3 2021
medline: 7 3 2021
Statut: epublish

Résumé

Diabetic ketoacidosis (DKA) is a well-known complication of diabetes mellitus with a significantly high mortality if not immediately and properly treated. Therefore, strategies for prevention of DKA are ever so important when managing diabetes mellitus, especially in the non-compliant patient population. Previously studies have suggested insulin pump use to carry an increased risk of DKA compared to insulin injections, while European studies suggest the opposite. We aimed to perform a retrospective cohort study to determine the risk of DKA in insulin pump versus injection in the United States. We utilized the Healthcare Cost and Utilization Project National Inpatient Sample (HCUP-NIS) 2017 database, which represents a 20% sample of all payer hospitalizations in the United States. These hospitalizations were systematically selected by the Agency for Healthcare Resources and Quality (AHRQ) and we included all type 1 diabetes mellitus patients over the age of 18 who were on insulin, either pump or injections, in our study. We found a total of 58,260 admissions for patients with type 1 DM. Of these, 7850 had insulin pump, 30,672 used insulin injection, and 19,738 had no prior insulin use. We found that insulin pump use, compared to injections, failed to predict a lower incidence of DKA in hospitalized patients. Although several studies from European countries have found a reduction of DKA risk with insulin pump use, in this study we found no clear significant difference in a United States-based study. While this may be possible due to different legislating and regulation organizations, further studies are warranted to further evaluate the benefit of either insulin dispensing modality.

Sections du résumé

BACKGROUND BACKGROUND
Diabetic ketoacidosis (DKA) is a well-known complication of diabetes mellitus with a significantly high mortality if not immediately and properly treated. Therefore, strategies for prevention of DKA are ever so important when managing diabetes mellitus, especially in the non-compliant patient population. Previously studies have suggested insulin pump use to carry an increased risk of DKA compared to insulin injections, while European studies suggest the opposite. We aimed to perform a retrospective cohort study to determine the risk of DKA in insulin pump versus injection in the United States.
METHODS METHODS
We utilized the Healthcare Cost and Utilization Project National Inpatient Sample (HCUP-NIS) 2017 database, which represents a 20% sample of all payer hospitalizations in the United States. These hospitalizations were systematically selected by the Agency for Healthcare Resources and Quality (AHRQ) and we included all type 1 diabetes mellitus patients over the age of 18 who were on insulin, either pump or injections, in our study.
RESULTS RESULTS
We found a total of 58,260 admissions for patients with type 1 DM. Of these, 7850 had insulin pump, 30,672 used insulin injection, and 19,738 had no prior insulin use. We found that insulin pump use, compared to injections, failed to predict a lower incidence of DKA in hospitalized patients.
CONCLUSION CONCLUSIONS
Although several studies from European countries have found a reduction of DKA risk with insulin pump use, in this study we found no clear significant difference in a United States-based study. While this may be possible due to different legislating and regulation organizations, further studies are warranted to further evaluate the benefit of either insulin dispensing modality.

Identifiants

pubmed: 33668749
pii: jcm10050898
doi: 10.3390/jcm10050898
pmc: PMC7956187
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Treat Endocrinol. 2003;2(2):95-108
pubmed: 15871546
Pediatr Diabetes. 2006 Aug;7 Suppl 4:32-8
pubmed: 16774616
JAMA. 2017 Oct 10;318(14):1358-1366
pubmed: 29049584
Diabetologia. 2012 Aug;55(8):2295-7
pubmed: 22588587
Diabetes Care. 1984 Nov-Dec;7(6):528-32
pubmed: 6439530
BMJ Open. 2017 Aug 1;7(7):e016587
pubmed: 28765134
Diabetes Care. 2015 Apr;38(4):716-22
pubmed: 25776138
Diabetes Technol Ther. 2016 Nov;18(11):713-718
pubmed: 27860498
BMJ. 2016 Feb 25;352:i969
pubmed: 26916049
Diabetes Care. 2003 Apr;26(4):1079-87
pubmed: 12663577
Med Clin North Am. 2017 May;101(3):587-606
pubmed: 28372715
Cureus. 2019 May 31;11(5):e4789
pubmed: 31372327
Diabetes Technol Ther. 2017 Jun;19(S3):S60-S66
pubmed: 28585871
Diabetes Technol Ther. 2019 Aug;21(8):440-447
pubmed: 31199682
Am J Ther. 2020 Jan/Feb;27(1):e30-e41
pubmed: 31833871

Auteurs

Abbas Alshami (A)

Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, USA.

Tiffany Purewal (T)

Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, USA.

Steven Douedi (S)

Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, USA.

Mohammed Alazzawi (M)

Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, USA.

Mohammad A Hossain (MA)

Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, USA.

Raquel Ong (R)

Division of Endocrinology, Diabetes, and Metabolism, Jersey Shore University Medical Center, Neptune, NJ 07753, USA.

Shuvendu Sen (S)

Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, USA.

Jennifer Cheng (J)

Division of Endocrinology, Diabetes, and Metabolism, Jersey Shore University Medical Center, Neptune, NJ 07753, USA.

Swapnil Patel (S)

Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, USA.

Classifications MeSH